These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31944835)

  • 1. HIV Outbreak Control With Effective Access to Care and Harm Reduction in North Carolina, 2017-2018.
    Samoff E; Mobley V; Hudgins M; Cope AB; Adams ND; Caputo CR; Dennis AM; Billock RM; Crowley CA; Clymore JM; Foust E
    Am J Public Health; 2020 Mar; 110(3):394-400. PubMed ID: 31944835
    [No Abstract]   [Full Text] [Related]  

  • 2. Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm Reduction Coalition.
    Cloud DH; Castillo T; Brinkley-Rubinstein L; Dubey M; Childs R
    Curr HIV/AIDS Rep; 2018 Jun; 15(3):276-282. PubMed ID: 29740734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention knowledge, risk behaviours and seroprevalence among nonurban injectors of southwest Connecticut.
    Grau LE; Zhan W; Heimer R
    Drug Alcohol Rev; 2016 Sep; 35(5):628-36. PubMed ID: 27073014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of Contact Tracing and Phylogenetics in an Investigation of Acute HIV Infection.
    Dennis AM; Pasquale DK; Billock R; Beagle S; Mobley V; Cope A; Kuruc J; Sebastian J; Walworth C; Leone PA
    Sex Transm Dis; 2018 Apr; 45(4):222-228. PubMed ID: 29465708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Immunodeficiency Virus (HIV) Outbreak Investigation Among Persons Who Inject Drugs in Massachusetts Enhanced by HIV Sequence Data.
    Tumpney M; John B; Panneer N; McClung RP; Campbell EM; Roosevelt K; DeMaria A; Buchacz K; Switzer WM; Lyss S; Cranston K
    J Infect Dis; 2020 Sep; 222(Suppl 5):S259-S267. PubMed ID: 32877558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy of needle exchange programs in the prevention of HIV and hepatitis infection among injecting drug users].
    Takács IG; Demetrovics Z
    Psychiatr Hung; 2009; 24(4):264-81. PubMed ID: 19949245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015.
    Peters PJ; Pontones P; Hoover KW; Patel MR; Galang RR; Shields J; Blosser SJ; Spiller MW; Combs B; Switzer WM; Conrad C; Gentry J; Khudyakov Y; Waterhouse D; Owen SM; Chapman E; Roseberry JC; McCants V; Weidle PJ; Broz D; Samandari T; Mermin J; Walthall J; Brooks JT; Duwve JM;
    N Engl J Med; 2016 Jul; 375(3):229-39. PubMed ID: 27468059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Reported Injection Behaviors Following the Public Health Response to an HIV Outbreak Among People Who Inject Drugs: Indiana, 2016.
    Dasgupta S; Broz D; Tanner M; Patel M; Halleck B; Peters PJ; Weidle PJ; O'Donnell J; Amlung J; McAlister C; Chapman E; Bailey A; Burnett J; Duwve J
    AIDS Behav; 2019 Dec; 23(12):3257-3266. PubMed ID: 31313095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
    Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
    Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to Syringe Services Programs - Kentucky, North Carolina, and West Virginia, 2013-2017.
    Bixler D; Corby-Lee G; Proescholdbell S; Ramirez T; Kilkenny ME; LaRocco M; Childs R; Brumage MR; Settle AD; Teshale EH; Asher A
    MMWR Morb Mortal Wkly Rep; 2018 May; 67(18):529-532. PubMed ID: 29746453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.
    van Beek I; Chronister KJ
    Int J Drug Policy; 2015 Sep; 26(9):868-74. PubMed ID: 26118797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs.
    Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Turcotte MÈ; Bruneau J
    Am J Prev Med; 2020 Jun; 58(6):845-853. PubMed ID: 32444003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An assessment of an HIV prevention intervention among people who inject drugs in the states of Manipur and Nagaland, India.
    Goswami P; Medhi GK; Armstrong G; Setia MS; Mathew S; Thongamba G; Ramakrishnan L; George B; Singh RK; Paranjape RS; Mahanta J
    Int J Drug Policy; 2014 Sep; 25(5):853-64. PubMed ID: 24925819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Service utilization and cost of implementing a comprehensive HIV prevention and care program among people who inject drugs in Delhi, India.
    Sebastian MP; Dasgupta A; Saraswati LR; Singh A; Sharma V; Madan I; Tun W; Pulerwitz J; Thior I; Sarna A
    Harm Reduct J; 2017 Jun; 14(1):38. PubMed ID: 28615077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who: four ways to reduce hepatitis infections in people who inject drugs.
    Cent Eur J Public Health; 2012 Sep; 20(3):207. PubMed ID: 23285521
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent and Rapid Transmission of HIV Among People Who Inject Drugs in Scotland Revealed Through Phylogenetic Analysis.
    Ragonnet-Cronin M; Jackson C; Bradley-Stewart A; Aitken C; McAuley A; Palmateer N; Gunson R; Goldberg D; Milosevic C; Leigh Brown AJ
    J Infect Dis; 2018 May; 217(12):1875-1882. PubMed ID: 29546333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
    Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
    Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of on-site and outreach-based needle and syringe programs in people who inject drugs in Kermanshah, Iran.
    Nazari SS; Noroozi M; Soori H; Noroozi A; Mehrabi Y; Hajebi A; Sharifi H; Higgs P; Mirzazadeh A
    Int J Drug Policy; 2016 Jan; 27():127-31. PubMed ID: 26764125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of Injection-Related Risk Behaviors After Emergency Implementation of a Syringe Services Program During an HIV Outbreak.
    Patel MR; Foote C; Duwve J; Chapman E; Combs B; Fry A; Hall P; Roseberry J; Brooks JT; Broz D
    J Acquir Immune Defic Syndr; 2018 Apr; 77(4):373-382. PubMed ID: 29271829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.